Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264072 | 0.83 | ALDH1A1 (0.57) | MEN1LMNAKMT2ACYP1A2MAPT | |
| SCHEMBL28103573 | 0.80 | PDE4B (0.77) | PDE4BTYK2MEN1LMNAKMT2A | |
| SCHEMBL5265201 | 0.76 | PDE4B (0.60) | PDE4BMEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL28103925 | 0.75 | PDE4B (0.66) | PDE4BSYK | |
| SCHEMBL28103922 | 0.75 | PDE4B (0.73) | PDE4BTYK2MEN1LMNAKMT2A | |
| SCHEMBL27930309 | 0.74 | PDE4B (0.69) | PDE4BTYK2MAPK8ZAP70SYK | |
| SCHEMBL5914453 | 0.73 | ALDH1A1 (0.45) | PDE4BMEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL28103913 | 0.72 | PDE4B (0.69) | PDE4BMEN1KMT2AMAPK8SYK | |
| SCHEMBL5316612 | 0.72 | PDE4B (0.43) | PDE4BMEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL3256027 | 0.70 | MEN1 (0.55) | PDE4BMEN1LMNAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | PDE4B 2694/4885TYK2 581/4885MEN1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.